Vera Therapeutics, Inc. (NASDAQ:VERA) Holdings Raised by Avoro Capital Advisors LLC

Avoro Capital Advisors LLC lifted its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 30.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,610,000 shares of the company's stock after buying an additional 1,300,410 shares during the period. Vera Therapeutics makes up about 3.4% of Avoro Capital Advisors LLC's portfolio, making the stock its 9th largest position. Avoro Capital Advisors LLC owned approximately 8.86% of Vera Therapeutics worth $237,247,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the company. FMR LLC boosted its stake in Vera Therapeutics by 9.6% in the 4th quarter. FMR LLC now owns 3,053,126 shares of the company's stock worth $129,117,000 after purchasing an additional 267,842 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Vera Therapeutics by 14.3% in the fourth quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company's stock worth $124,737,000 after buying an additional 369,387 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Vera Therapeutics by 14.8% during the fourth quarter. Geode Capital Management LLC now owns 1,153,325 shares of the company's stock worth $48,787,000 after buying an additional 148,660 shares during the period. Federated Hermes Inc. grew its holdings in shares of Vera Therapeutics by 162.2% during the fourth quarter. Federated Hermes Inc. now owns 1,085,986 shares of the company's stock valued at $45,926,000 after buying an additional 671,881 shares during the last quarter. Finally, Pictet Asset Management Holding SA increased its position in shares of Vera Therapeutics by 47.1% in the 4th quarter. Pictet Asset Management Holding SA now owns 841,313 shares of the company's stock valued at $35,579,000 after acquiring an additional 269,315 shares during the period. Institutional investors own 99.21% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on VERA. JPMorgan Chase & Co. lowered their price target on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research report on Tuesday, March 4th. Wolfe Research began coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 target price on the stock. Guggenheim raised their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Finally, The Goldman Sachs Group started coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $64.67.

Vera Therapeutics Price Performance

Shares of Vera Therapeutics stock traded up $0.95 during trading hours on Wednesday, reaching $22.34. The stock had a trading volume of 1,124,338 shares, compared to its average volume of 749,365. The firm has a market capitalization of $1.42 billion, a PE ratio of -8.56 and a beta of 1.28. The stock's 50 day moving average is $25.46 and its 200 day moving average is $36.13. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11. Equities analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.